返回

Sanford Health
学者数1.2K
论文数791
被引数422
关联论文 (787)
发表时间
Phase I Dose Escalation/Dose Expansion Trial of NBTXR3/SBRT in Combination with Nivolumab or Pembrolizumab for the Treatment of Anti-PD-1 Naïve or Resistant Patients with Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaI期NBTXR3/SBRT联合纳武利尤单抗或帕博利珠单抗治疗抗PD-1耐受或耐药的复发性/转移性头颈鳞状细胞癌患者的剂量递增/剂量扩展试验

